Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Clinical activity of eribulin in advanced desmoplastic small round-cell tumor

Emambux, Sheika; Kind, Micheleb; Le Loarer, Francoisc; Toulmonde, Mauda; Stoeckle, Eberhardd; Italiano, Antoinea

doi: 10.1097/CAD.0000000000000536

Desmoplastic small round-cell tumor is a rare but highly aggressive tumor occurring mainly in adolescents and young adults. Prolonged progression-free survival has been documented in patients who have undergone aggressive multimodality therapy – that is, multiagent intensive chemotherapy, debulking surgery, and radiation therapy. Eribulin is a microtubule-dynamics inhibitor, and it has recently been shown to be active in liposarcomas. In preclinical models, eribulin activities have also been shown to occur in Ewing’s sarcoma cell lines, rhabdomyosarcomas and osteosarcomas. In this study, we report three cases of male patients suffering from desmoplastic small round-cell tumor and the clinical response to eribulin in two of them.

Departments of aMedical Oncology



dSurgery, Institut Bergonie, Bordeaux, France

Correspondence to Antoine Italiano, MD, PhD, Department of Medical Oncology, Institut Bergonie, 229 Cours de l’Argonne, 33076 Bordeaux, France Tel: +33 547 306 088; fax: +33 547 306 083; e-mail:

Received March 24, 2017

Accepted June 6, 2017

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.